The impact of cerebrospinal fluid viral polymerase chain reaction testing on the management of adults with viral meningitis: A multi-center retrospective study.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
01 2023
Historique:
revised: 03 09 2022
received: 01 06 2022
accepted: 04 10 2022
pubmed: 8 10 2022
medline: 11 1 2023
entrez: 7 10 2022
Statut: ppublish

Résumé

The aim of this study was to evaluate the role of viral polymerase chain reaction (PCR) testing in patients with aseptic meningitis and identify opportunities for improvement in clinical management. All cerebrospinal fluid samples collected in 1 year from four teaching hospitals in Sydney, Australia, were reviewed. Patients with aseptic meningitis were selected, and clinical and diagnostic features, hospital length of stay (LOS), and treatment were analyzed. Identifying a cause by viral PCR did not reduce hospital LOS (median 3 days) or antibiotic use (median 2 days), but the turnaround time of the PCR test correlated with LOS (Rs = 0.3822, p = 0.0003). Forty-one percent of patients received intravenous acyclovir treatment, which was more frequent in patients admitted under neurologists than infectious diseases physicians (56% vs. 24%; p = 0.013). The majority of patients did not have investigations for alternative causes of aseptic meningitis such as human immunodeficiency virus and syphilis if the viral PCR panel was negative. The benefit of PCR testing in aseptic meningitis in adults in reducing LOS and antibiotic use is unclear. The reasons for unnecessary aciclovir use in meningitis syndromes require further assessment.

Identifiants

pubmed: 36207770
doi: 10.1002/jmv.28198
pmc: PMC10092443
doi:

Substances chimiques

Anti-Bacterial Agents 0
Acyclovir X4HES1O11F

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28198

Informations de copyright

© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Références

Front Neurol. 2020 Dec 07;11:602267
pubmed: 33424752
QJM. 2002 Oct;95(10):663-70
pubmed: 12324638
J Clin Virol. 2008 Feb;41(2):75-80
pubmed: 18354820
J Clin Virol. 2018 Jul;104:56-60
pubmed: 29738895
BMC Pediatr. 2020 Apr 16;20(1):166
pubmed: 32299396
N Engl J Med. 1993 Jan 7;328(1):21-8
pubmed: 8416268
J Med Virol. 2002 May;67(1):47-53
pubmed: 11920817
Clin Infect Dis. 1998 Oct;27(4):896-8
pubmed: 9798053
J Med Virol. 2019 Oct;91(10):1882-1886
pubmed: 31180138
Emerg Med Australas. 2012 Feb;24(1):52-6
pubmed: 22313560
J Med Virol. 2009 Jan;81(1):42-8
pubmed: 19031461
Hosp Pediatr. 2019 Oct;9(10):763-769
pubmed: 31511395
Pediatr Infect Dis J. 2002 Apr;21(4):283-6
pubmed: 12075757
BMC Infect Dis. 2013 Oct 21;13:487
pubmed: 24138798
Clin Infect Dis. 2004 Sep 1;39(5):630-5
pubmed: 15356774
Clin Neurol Neurosurg. 2015 Feb;129:67-71
pubmed: 25553519
BMJ. 2008 Jan 5;336(7634):36-40
pubmed: 18174598
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 33055181
Neurology. 2006 Jan 10;66(1):75-80
pubmed: 16401850
J Clin Microbiol. 1998 Sep;36(9):2408-12
pubmed: 9705364
Clin Infect Dis. 2008 Aug 1;47(3):433-4
pubmed: 18605915
J Pediatr. 2017 Oct;189:169-174.e2
pubmed: 28705656
Clin Med (Lond). 2009 Dec;9(6):626-7
pubmed: 20095316
J Clin Virol. 2015 Jan;62:58-62
pubmed: 25542472
Medicine (Baltimore). 2016 Jan;95(2):e2372
pubmed: 26765411
Intern Med J. 2015 May;45(5):563-76
pubmed: 25955462
JAMA. 2000 May 24-31;283(20):2680-5
pubmed: 10819951
Med J Aust. 2018 Nov 19;209(10):449-454
pubmed: 30309300
J Med Virol. 2023 Jan;95(1):e28198
pubmed: 36207770
J Infect. 2016 Apr;72(4):405-38
pubmed: 26845731
Arch Pediatr Adolesc Med. 2000 Aug;154(8):817-21
pubmed: 10922279
Indian J Pediatr. 2005 Jan;72(1):57-63
pubmed: 15684450
Rev Neurol (Paris). 2019 Sep - Oct;175(7-8):475-480
pubmed: 31375286
Pediatr Infect Dis J. 1994 Mar;13(3):177-82
pubmed: 8177623
Pediatr Emerg Care. 2018 Nov;34(11):791-796
pubmed: 27898578

Auteurs

Myong Gyu Kim (MG)

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Clinical School of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.

Trine Gulholm (T)

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Clinical School of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.

Kate Lennard (K)

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia.

Feras Mirdad (F)

Department of Microbiology and Infectious Diseases, NSW Health Pathology and South Western Sydney Local Health District, Liverpool, New South Wales, Australia.

Kristen Overton (K)

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Clinical School of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.

Michael Maley (M)

Department of Microbiology and Infectious Diseases, NSW Health Pathology and South Western Sydney Local Health District, Liverpool, New South Wales, Australia.

Pamela Konecny (P)

Clinical School of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.
Department of Infectious Diseases and Immunology, St. George Hospital, Kogarah, New South Wales, Australia.

David Andresen (D)

Departments of Infectious Diseases and Microbiology, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia.
St. Vincent's Hospital Clinical School of medicine, University of Notre Dame, Sydney, New South Wales, Australia.

Jeffrey John Post (JJ)

Department of Infectious Diseases, Prince of Wales Hospital, Randwick, New South Wales, Australia.
Clinical School of Medicine, UNSW Sydney, Kensington, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH